Robust neutralizing antibody response to SARS-CoV-2 mRNA vaccination in adolescents and young adults with childhood-onset rheumatic diseases
Authors:
Open Access
- 23 February 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 61 (11) , 4472-4481
Abstract
Objectives: Immunogenicity to the SARS-CoV-2 mRNA vaccines in adolescents and young adults (AYA) with childhood-onset rheumatic diseases (cRD) is unknown. We aimed to evaluate the humoral immunogenicity and safety of the vaccines in our AYA with cRD. Methods: A monocentric observational study with 159 AYA (50.3% female and 70.4% Chinese). Humoral immunogenicity was assessed at 2–3 and 4–6 weeks following first and second vaccination by cPass™ SARS-CoV-2 Neutralization Antibody Assay. Inhibition signal of ≥30% defined the cut-off for positive detection of the SARS-CoV-2 neutralizing antibodies. Vaccine safety and disease activity were assessed within 6 weeks after second vaccination. Results: A total of 64.9% and 99.1% of 159 patients (median age: 16.9, IQR: 14.7–19.5) mounted positive SARS-CoV-2 neutralizing responses after first and second vaccination, respectively. Most patients (89.8%) had ≥90% inhibition signal after second vaccination. Methotrexate and mycophenolate mofetil increased the risk associated with negative cPass neutralization responses following the first vaccination. Holding both medications after each vaccination did not affect immunogenicity. There was no symptomatic COVID-19 infection. Local reaction remained the most common (23.3–25.2%) adverse event, without serious complication. Two and seven patients flared following the first and second vaccination, respectively. Subgroup analyses of the 12–18-year-old cohort did not show any differences in vaccine efficacy, predictors of poor response and general safety, but higher proportion of disease flares. Conclusions: SARS-CoV-2 mRNA vaccines were efficacious after the two-dose regimen in almost all AYA with cRD without serious adverse event. The rate of disease flare observed is 4.4% after the second mRNA vaccine dose.Keywords
Funding Information
- SingHealth Duke-NUS Academic Medicine COVID-19 Rapid Response Research (AM/COV004/2020)
- National Research Foundation Singapore
- National Medical Research Council
- Centre Grant Programme (NMRC/CG/M003/2017)
- Ministry of Health, Singapore’s NMRC (NMRC/TA/0059/2017, MNRC/MOHIAFCAT2/005/2015, NMRC/TCR/0015-NCC/2016, NMRC/OFLCG/002/2018, NMRC/STPRG-FY19-001, NMRC/COVID19RF-003)
This publication has 38 references indexed in Scilit:
- A New SARS-CoV-2 Dual-Purpose Serology Test: Highly Accurate Infection Tracing and Neutralizing Antibody Response DetectionJournal of Clinical Microbiology, 2021
- COVID-19 outbreak: Migration, effects on society, global environment and preventionScience of The Total Environment, 2020
- A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interactionNature Biotechnology, 2020
- The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patientsScience Immunology, 2020
- Comparison of Clinical Characteristics of Patients with Asymptomatic vs Symptomatic Coronavirus Disease 2019 in Wuhan, ChinaJAMA Network Open, 2020
- Clinical Characteristics of Coronavirus Disease 2019 in ChinaNew England Journal of Medicine, 2020
- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in ChinaJAMA, 2020
- A Genomic Perspective on the Origin and Emergence of SARS-CoV-2Cell, 2020
- Structural basis of receptor recognition by SARS-CoV-2Nature, 2020
- Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registriesArthritis Research & Therapy, 2018